[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Sugarbaker PH, Bijelic L: The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Tumori; 2008 Sep-Oct;94(5):694-700
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • BACKGROUND: A successful new treatment for a particular disease may change the natural history of that disease as patients go on to longer survival.
  • The goal of this study was to investigate the porta hepatis as a site of recurrence of appendiceal mucinous neoplasms.
  • METHODS: A prospective database on patients with peritoneal dissemination of mucinous appendiceal neoplasms has been maintained for 21 years.
  • RESULTS: In 710 patients treated for mucinous appendiceal cancer with a complete cytoreduction, 140 developed recurrent disease.
  • Four of the seven had biliary obstruction and three had masses within the liver hilum not causing bile duct obstruction.
  • Four of the seven patients were successfully palliated by surgical procedures within the liver and biliary tree.
  • CONCLUSIONS: Progression of mucinous neoplasms within the porta hepatis may be related to imperfect cytoreduction technique.
  • Reoperative surgical treatment and biliary stents were beneficial in some of these patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendectomy. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Appendicitis / surgery. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Perioperative Care. Prospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112943.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Zhao Y, An X, Xiang XJ, Feng F, Wang FH, Wang ZQ, Xu RH, He YJ, Li YH: [Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients]. Chin J Cancer; 2010 Jan;29(1):102-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: Oxaliplatin is one of the effective drugs for the treatment of advanced colorectal cancer (CRC).
  • METHODS: Clinical data of 109 patients with advanced CRC receiving oxaliplatin plus capecitabine (the XELOX regimen) as first-line therapy were collected and analyzed retrospectively.
  • Allergic reactions usually occurred at the median time during the fifth cycle (range, the 1st-8th cycle) of oxaliplatin-containing therapy, and the cumulative oxaliplatin dose was 1200 mg (range, 400-1600 mg).
  • Symptoms associated with anaphylaxis appeared 5-360 min (median, 180 min) after oxaliplatin infusion, and were relieved after withdrawing the oxaliplatin infusion and treating with antiallergic drugs.
  • A total of 8 patients continued to receive oxaliplatin therapy after prophylactic administration of antiallergic drugs, such as steroids, and 4 patients did not report persistent allergic reactions.
  • Compared with men, oxaliplatin-induced allergic reactions were more commonly seen in women patients (P<0.05), while age, body surface area, performance status, tumor location, and pathologic type showed no significant difference.
  • CONCLUSION: Oxaliplatin-induced allergic reactions occurred in Chinese patients with CRC, and the incidence rate, occurrence time, degree of severity, and clinical outcome were consistent with literature published abroad.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / adverse effects. Colorectal Neoplasms / drug therapy. Drug Hypersensitivity / etiology. Organoplatinum Compounds / adverse effects
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adolescent. Adult. Aged. Anaphylaxis / drug therapy. Anaphylaxis / etiology. Anti-Allergic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Asian Continental Ancestry Group. Capecitabine. Child. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038320.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil; XELOX
  •  go-up   go-down


3. Pahlavan PS, Kanthan R: The epidemiology and clinical findings of colorectal cancer in Iran. J Gastrointestin Liver Dis; 2006 Mar;15(1):15-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-mucinous adenocarcinoma (AC) was the most common histological type (n=181, 90%), followed by mucinous AC (n=15), squamous cell carcinoma (n=1), carcinoid (n=1), melanoma (n=1) and signet ring carcinoma (n=1).
  • Younger patients had a greater preponderance of mucinous AC (p=0.008) and generally underwent more extensive chemotherapy as seen with more usage of 5-Fluorouracil (p=0.05).
  • We found no significant difference between age, gender and type of cancer with subsite distribution.
  • Distal CRC was more prevalent.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680227.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


Advertisement
4. Pandey M, Kumar V, Shukla M, Kumar M: Thyroid swelling in a 32-year-old male. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with intrathyroidal metastasis may present with previous history of malignancy or they may present with a secondary neoplasm prompting us to search for the primary site.
  • Fine-needle aspiration cytology from the thyroid swelling revealed deposits from the mucinous adenocarcinoma.
  • The further diagnostic and metastatic work-up identified a diffuse carcinoma of the stomach as the primary site with liver as secondary and retroperitoneal lymph nodes having mucinous deposits with associated Peutz-Jeghers polyposis.
  • Preoperative diagnosis, proper evaluation and high degree of suspicion may avoid unnecessary thyroidectomy and effective palliation can be achieved with chemotherapy in view of disseminated disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):581-7 [16983577.001]
  • [Cites] Anticancer Res. 2008 Sep-Oct;28(5B):2885-8 [19031929.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):896-9 [9634427.001]
  • [Cites] World J Surg. 1999 Feb;23(2):177-80; discussion 181 [9880428.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):127-35 [9916927.001]
  • (PMID = 21686341.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028274
  •  go-up   go-down


5. Ishiguro A, Munakata M, Shitara K, Kasai M, Sakata Y: [A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1457-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction].
  • A 74-year-old man was revealed to have type 3 gastric cancer with lymph-node metastasis in the third group (N 3) and liver metastasis (H 1).
  • Since we regarded a curative operation as impossible, we started preoperative chemotherapy using TS-1 plus irinotecan hydrochloride (CPT-11) on the premise that we would perform surgical cytoreduction after the chemotherapy.
  • After two courses of chemotherapy, both the primary lesion and the liver metastasis were reduced in size, and the paraaortic lymph-nodes disappeared.
  • Subsequently, a distal gastrectomy (D 0, curability C) was performed.
  • The patient has been receiving postoperative chemotherapy using TS-1 and paclitaxel as an outpatient for 2.3 years.
  • Although there is not enough evidence to support the benefit of surgical cytoreduction, chemotherapy combined with surgical cytoreduction would improve the survival time without deterioration of quality of life (QOL) in patients with advanced gastric cancer.
  • This combined therapy should be considered as one of the promising strategies for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Oxonic Acid / administration & dosage. Quality of Life. Survivors. Tegafur / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033237.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Masellis AM, Sielaff TD, Bender GP: Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens. Int J Clin Oncol; 2009 Oct;14(5):478-81
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
  • Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the United States.
  • Current 5-year survival is less than 4%, highlighting the dire need for effective treatment.
  • We report the case of a 41-year-old woman who was diagnosed with advanced metastatic well-to-moderately differentiated mucinous adenocarcinoma of the pancreas, involving the liver and peritoneal cavity.
  • She agreed to receive novel combination chemotherapy rather than the standard-of-care treatment.
  • Complete response of multiple liver and peritoneal metastases and reduction in size with increasing calcification of the pancreatic mass occurred in this patient after 18 months of treatment.
  • This report documents the individual response to effective and well-tolerated treatment regimens integrating available drugs.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Albumins / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biopsy, Fine-Needle. Capecitabine. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Taxoids / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2007 Aug;34(4):347-53 [17674963.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75 [17440727.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Oct;60(5):759-66 [17285317.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1-20 [17291226.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Expert Opin Pharmacother. 2007 Nov;8(16):2719-27 [17956194.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 7:vii1-vii10 [17600091.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):525-33 [17577216.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:20-5 [18336394.001]
  • (PMID = 19856062.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 130-nm albumin-bound paclitaxel; 0 / Albumins; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Dong NN, Wang MY, Zhang Q, Liu ZF: [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. Ai Zheng; 2009 Apr;28(4):412-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
  • BACKGROUND AND OBJECTIVE: Combination therapy of oxaliplatin and capecitabine has certain effects on advanced gastric cancer (AGC).
  • This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients.
  • METHODS: Thirty-three chemotherapy-naive patients with AGC were entered into this study.
  • RESULTS: Thirty-three patients completed 159 cycles of chemotherapy with a median number of five cycles.
  • At a mean follow-up of 10.5 months, the median time to progression and overall survival were 5.9 (95% CI: 4.7-7.1) and 10.4 months (95% CI: 7.9-12.9), respectively.
  • CONCLUSION: XELOX is an effective and well-tolerated first-line chemotherapy regimen for patients with AGC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / secondary. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Diarrhea / chemically induced. Disease Progression. Female. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Peripheral Nervous System Diseases / chemically induced. Remission Induction. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622303.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; U3P01618RT / Fluorouracil; XELOX
  •  go-up   go-down


8. Maksimović S: [Survival rates of patients with mucinous adenocarcinoma of the colorectum]. Med Arh; 2007;61(1):26-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival rates of patients with mucinous adenocarcinoma of the colorectum].
  • PURPOSE: Mucinous adenocarcinoma is one of the histological subtypes of colorectal cancer.
  • Mucinous colorectal adenocarcinomas comprise approximately 1 to 6 percent of all colorectal epithelial cancers.
  • Frequently are more advanced at diagnosis and have a poorer prognosis than nonmucinous colorectal adenocarcinomas.
  • 39 patients had mucinous colorectal adenocarcinomas.
  • To determine whether the mucinous adenocarcinoma itself was independent prognostic factor in the curative resected patients, a multivariate analysis was performed.
  • RESULTS: The mucinous adenocarcinoma patients compared to patients with nonmucinous adenocarcinoma patients were found to be younger (p= 0,001), have more lymph node metastases (46,15% vs. 38,31%, p=0,0053), more peritoneal dissemination (20,51% vs. 5,1%, p <0,0001), greater frequency of advanced stage disease (p= 0,0006), lower rate of curative resection (76,3% vs. 84,9%, p=0,0045), and lower overall 5-year survival rates (39% vs. 60,3%, p=0,0002.
  • DISCUSSION: Conflicting results are found in the published literature regarding the relationship between mucinous colorectal cancer and survival.
  • Although the weight of the published literature suggests that mucinous adenocarcinoma is associated with poorer outcome, contradictory reports suggest that the clinical relevance of this histological type in this patient population remains unclear The lack of consensus may be attributable to the limited detection power inherent in studies that test small subsets of patients and the diversity inherent in the inclusion of patients with all Dukes' stages in the analysis.
  • Indeed, these series studied prognosis from initial diagnosis, generally in patients treated with surgery alone, and did not specifically address outcomes in patients treated with chemotherapy.
  • Therefore, published data on the responsiveness of mucinous CRC to chemotherapy are lacking.
  • Mucinous tumors were associated with a higher proportion of patients with nodal metastases and peritoneal metastases, while the most common site of metastases for patients with non-mucinous histology was the liver.
  • A higher proportion of peritoneal metastases in patients with mucinous CRC were also reported in previous studies.
  • CONCLUSIONS: The mucinous histological type itself was an independent factor for poor prognosis for patients who underwent curative surgery.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582971.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Bosnia and Herzegovina
  • [Number-of-references] 25
  •  go-up   go-down


9. Shibaki T, Morimoto N: [A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole]. Gan To Kagaku Ryoho; 2010 Mar;37(3):499-501
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
  • A 51-year-old woman, who had undergone mastectomy due to a mucinous carcinoma of her left breast, was diagnosed with solitary liver metastasis 7 months after operation.
  • Systemic chemotherapy consisting of 5 courses of FEC75 (cyclophosphamide 500 mg/m2, epirubicin 75 mg/m2, and 5-FU 500 mg/m2 on 1st day, with 1 course for 21 days) was followed by sequential hormonal therapy with tamoxifen citrate and letrozole.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Nitriles / therapeutic use. Tamoxifen / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. LETROZOLE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332691.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 3Z8479ZZ5X / Epirubicin; 7LKK855W8I / letrozole; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Meguro E, Kaizuka H, Inaba T, Irinoda T, Hayakawa Y, Okada S, Yamaguchi S, Wakabayashi J: [A case of advanced gastric cancer which became operable after chemotherapy with combination of TS-1/CDDP and in which complete disappearance of liver metastasis was histopathologically confirmed]. Gan To Kagaku Ryoho; 2003 Jun;30(6):863-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer which became operable after chemotherapy with combination of TS-1/CDDP and in which complete disappearance of liver metastasis was histopathologically confirmed].
  • We encountered a patient in whom TS-1/cisplatin (CDDP) combination chemotherapy was effective.
  • The cancer became operable, and complete disappearance of liver metastasis was histopathologically confirmed.
  • Based on upper GI endoscopy and abdominal CT, type 1 gastric cancer associated with liver and abdominal lymph node metastases was diagnosed.
  • The cancer was judged to be inoperable, and chemotherapy with a combination of TS-1 and CDDP was initiated.
  • One course of treatment consisted of administration of 120 mg/day of TS-1 for 21 days followed by 14 days of withdrawal, and administration of 100 mg/body/day of CDDP on day 8 (80 mg/body/day in the second course).
  • After two courses of treatment, the primary lesion and the liver and lymph node metastatic lesions decreased in size (reduction ratios were 42.3%, 90.5% and 85.2%, respectively).
  • The only adverse event of Grade 2 or more severity observed during drug administration was anorexia.
  • Liver metastasis was judged from pathological findings to have disappeared.
  • TS-1/CDDP therapy is believed to provide effective treatment against liver metastasis and lymph node metastasis of gastric cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Gastrectomy. Hepatectomy. Humans. Lymphatic Metastasis. Male. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Splenectomy. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12852358.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Adham M, Jaeck D, Le Borgne J, Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, Scoazec JY, Mornex F, Partensky C: Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas; 2008 Nov;37(4):352-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.
  • OBJECTIVES: Long-term survival after pancreatectomy for pancreatic duct adenocarcinoma has been rarely reported.
  • The aim of the study is to report a French multicentric series of long-term survivors after pancreatectomy for pancreatic duct adenocarcinoma.
  • Patients with intraductal-papillary-mucinous-neoplasia, cystadenocarcinoma, acinous-adenocarcinoma, neuroendocrine, or mixed tumors were excluded.
  • Three patients had portal vein resection, 1 had hepatic artery resection-reconstruction, and 1 had segmentectomy for liver metastasis.
  • Twenty patients had adjuvant radiotherapy, and 18 had concomitant chemotherapy.
  • CONCLUSIONS: Pancreatic duct adenocarcinoma can be cured, and long-term survival after R0 curative surgery has become a reality.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. France / epidemiology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pancreas. 2008 Nov;37(4):349-51 [18953246.001]
  • (PMID = 18665012.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


12. Turrini O, Viret F, Guiramand J, Lelong B, Bège T, Delpero JR: Strategies for the treatment of synchronous liver metastasis. Eur J Surg Oncol; 2007 Aug;33(6):735-40
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for the treatment of synchronous liver metastasis.
  • AIM: Observe the outcomes after complete simultaneous or delayed resection of synchronous liver metastasis (SLM) from colorectal cancer (CRC).
  • Perioperative chemotherapy was considered completed if all expected cycle were administrated.
  • The median survival time of group I-group II were respectively 46 months-40 months (p=0,07).
  • Patients with simultaneous or staged resection receiving optimal treatment (R0 liver surgery and complete chemotherapy) were respectively 89% and 67% (p=0,04).
  • Twenty three patients developed isolated liver recurrence with higher frequency in staged patients (26% vs 9% p=0,03) without impairment of survival.
  • CONCLUSIONS: Because of postoperative morbidity and prolonged tiring treatment, many patients having staged resection were under treated.
  • However we did not observe statistical difference on survival but we supported that simultaneous resection has to be prefer to achieve an optimal treatment.
  • [MeSH-major] Colonic Neoplasms / surgery. Liver Neoplasms / secondary. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Catheter Ablation. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Laparotomy. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400418.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. da Silva RG, Sugarbaker PH: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg; 2006 Dec;203(6):878-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
  • BACKGROUND: Although lymph node and liver metastases are recognized as indications for resection of metastatic disease from colorectal cancer, carcinomatosis has not traditionally been regarded as having surgical treatment options.
  • Reports have suggested that complete surgical removal of carcinomatosis combined with thorough irrigation of the peritoneal cavity with chemotherapy could result in longterm survival in selected patients.
  • Eleven clinical and treatment factors were studied in univariate and multivariable analyses using survival as an end point.
  • The difference in negative versus positive lymph nodes was also significant; differences in survival that were improved but not significant were present for age greater than 30 years, mucinous histology, location within the colon versus rectum, and absence of an adverse factor such as cancer perforation or obstruction present at the time of primary cancer resection.
  • CONCLUSIONS: Favorable longterm results of complete cytoreduction in patients treated for carcinomatosis are associated with a limited volume of carcinomatosis observed at the time of cytoreduction and in patients with negative lymph nodes at the time of primary operation.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / pathology. Perioperative Care. Peritoneal Lavage. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. Peritoneum / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Hyperthermia, Induced. Lymphatic Metastasis. Male. Middle Aged. Mitomycin / administration & dosage. Prognosis. Survival Rate. Therapeutic Irrigation

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116556.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Hu JL, Huang JJ, Fu XH: [Survival status and prognostic factors of liver metastases from colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):286-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival status and prognostic factors of liver metastases from colorectal cancer].
  • OBJECTIVE: To analyze the survival status and prognostic factors of patients with liver metastases from colorectal cancer.
  • METHODS: The survival rate and prognostic factors of 112 patients with liver metastases from colorectal cancer, who had complete follow-up data, were retrospectively assessed by Kaplan-Meier analysis and multivariate regression analysis.
  • RESULTS: The median survival time of the 112 patients was 18.25 months.
  • Univariate analysis demonstrated that gender, age, primary tumor site, chemotherapy and pathological types had no significant correlation with the overall survival.
  • But the treatment of primary tumor, time of liver metastasis, gross type of tumor, resection of liver metastases and clinical stage status were all independently related with the prognosis of patients.
  • Multivariate regression analysis showed that resection of liver metastases, gross type of tumor and clinical stage were key factors affecting the prognosis of patients with liver metastases from colorectal cancer.
  • CONCLUSION: Patients with advanced stage, infiltrative gross type of colorectal cancer should be followed-up closely so that liver metastases from the cancer can be diagnosed and treated early.
  • Resection of both the primary tumor and liver metastasis may improve survival of the patients.
  • [MeSH-major] Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510081.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Kaibori M, Iwamoto S, Ishizaki M, Matsui K, Saito T, Yoshioka K, Hamada Y, Kwon AH: Timing of resection for synchronous liver metastases from colorectal cancer. Dig Dis Sci; 2010 Nov;55(11):3262-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing of resection for synchronous liver metastases from colorectal cancer.
  • BACKGROUND: This study aimed to compare the surgical outcome and long-term survival between simultaneous and delayed resection of liver metastases from colorectal cancer (LM), and to identify the factors influencing hepatic disease-free survival in patients with synchronous LM.
  • METHODS: Seventy-four patients with LM were divided into two groups, i.e., 32 patients who underwent hepatectomy at the time of colorectal surgery (simultaneous group) and 42 patients who underwent delayed liver resection (delayed group).
  • RESULTS: The hepatic disease-free survival rates of patients from the delayed group with either ≥ 3 or <3 liver metastases were significantly better than that of the simultaneous group.
  • These patients had a higher incidence of poorly differentiated or mucinous adenocarcinoma, shorter interval between procedures, and larger tumors than patients without tumor progression.
  • Delayed resection of synchronous LM may be useful to reduce the risk of rapid recurrence in the remnant liver.
  • Patients with poorly differentiated or mucinous adenocarcinoma and those with larger tumors who undergo delayed liver resection should receive neoadjuvant chemotherapy during the interval between operations.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Proportional Hazards Models. Risk Factors. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Dis Sci. 2010 Dec;55(12):3634-5 [20552399.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):938-46 [9060531.001]
  • [Cites] J Gastrointest Surg. 2008 Aug;12(8):1391-8 [18491195.001]
  • [Cites] Br J Surg. 1992 Oct;79(10):1095-101 [1330197.001]
  • [Cites] Dis Colon Rectum. 1999 May;42(5):632-9 [10344686.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):749-54 [7172942.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Surg Gynecol Obstet. 1970 Oct;131(4):697-700 [5458530.001]
  • [Cites] Br J Surg. 2001 Jul;88(7):980-5 [11442531.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1498-504; discussion 1504-5 [17849166.001]
  • [Cites] Ann Surg. 1989 Feb;209(2):211-8 [2916865.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1136-40 [9278662.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Ann R Coll Surg Engl. 1994 Jan;76(1):59-64 [8117023.001]
  • [Cites] World J Surg. 1982 Jan;6(1):32-45 [7090394.001]
  • [Cites] Surgery. 2004 Sep;136(3):650-9 [15349115.001]
  • [Cites] Arch Surg. 2000 Apr;135(4):473-9; discussion 479-80 [10768715.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):195-201 [17080238.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1032-5 [8402060.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1310-6 [15484344.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):62-7 [1994607.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1143-50 [17200913.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):274-6 [8472130.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):956-62 [12905548.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2321-8 [10521990.001]
  • [Cites] World J Surg. 1998 Mar;22(3):268-76; discussion 276-7 [9494419.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):109-15; discussion 116-7 [12559192.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • (PMID = 20112062.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Zhang S, Gao F, Luo J, Yang J: Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis. Colorectal Dis; 2010 Aug;12(8):754-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis.
  • AIM: To determine the factors affecting the survival in colorectal cancer patients with synchronous liver metastases.
  • METHOD: A total of 168 patients who had been treated colorectal cancer with synchronous liver metastases at Guangxi Medical University from January 2000 to December 2005 were identified.
  • Criteria studied consisted of gender, age, time of symptoms, primary tumour location, primary tumour circumference, histological type, grade (tumour differentiation), T-status, N-status, large bowel obstruction, type of operation, primary tumour resection, ascities, location, number and diameter of liver lesions, preoperative CEA and chemotherapy.
  • RESULTS: The mean survival time for all patients was 18.71 (SEM = 1.59) months.
  • Univariate analysis share of grade (tumour differentiation), N-status, large bowel obstruction, operation, primary tumour resection, location, number and the most diameter of liver lesions, extrahepatic transfer, preoperative CEA level and chemotherapy to be predictors of survival.
  • In the Cox regression analysis, the N-status, large bowel obstruction, operation, diameter of liver lesion and extrahepatic transfer were independent factors related to survival.
  • CONCLUSION: Tumour differentiation, N-status, bowel obstruction, operation, primary tumour resection, location of liver metastasis, number of liver metastasis, diameter of liver metastasis, extrahepatic transfer, preoperative CEA level and chemotherapy are related to the survival of patients with colorectal cancer and synchronous liver metastases.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoembryonic Antigen / blood. Colon / pathology. Colon / surgery. Female. Humans. Intestinal Obstruction / mortality. Intestinal Obstruction / pathology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Regression Analysis. Retrospective Studies. Risk Factors. Sex Characteristics. Time Factors. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508508.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


17. Fang H, Wang XY, Wang JW, Zhang HG, Feng FY, Shi YK: [Analysis of prognostic factors in 300 colorectal cancer patients with liver metastases]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):220-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic factors in 300 colorectal cancer patients with liver metastases].
  • OBJECTIVE: To analyse the clinical characteristics and potential prognostic factors of colorectal cancer patients with liver metastases.
  • METHODS: The clinical and pathological data of 300 colorectal cancer patients with liver metastases were retrospectively reviewed and analyzed.
  • RESULTS: The median survival time of these patients was 19.0 months.
  • The 1-, 2- and 5-year survival rates after liver metastases were 79.0%, 29.0% and 3.0%, respectively.
  • Univariate analysis revealed that performance status (KPS), histological grading, primary tumor, N status, lymphatic and vascular invasion, stage at diagnosis, the number, size and distribution of liver metastases and other accompanied metastases were prognostic factors.
  • Multivariate analysis showed that KPS, lymphatic and vascular invasion, the number and size of liver metastases were independent prognostic factors of colorectal cancer with liver metastases.
  • CONCLUSION: Performance status, lymphatic and vascular invasion, the number and size of liver metastases are independent prognostic factors of colorectal cancer with liver metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615265.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Tanaka K, Shimada H, Fujii Y, Endo I, Sekido H, Togo S, Ike H: Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver. Langenbecks Arch Surg; 2004 Oct;389(5):371-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver.
  • BACKGROUND: Attempts at identifying prognostic factors after hepatectomy in patients with colorectal liver metastases have not achieved consensus.
  • METHOD: Clinicopathological data for 149 consecutive patients with colorectal cancer who underwent curative resection of primary lesions and metastatic liver disease at one institution were subjected to multivariate analysis concerning metastatic status and the primary lesion.
  • RESULTS: Poorly differentiated adenocarcinoma or mucinous carcinoma as the primary tumor (Poor/muc; P=0.026), marked vascular invasion by the primary tumor (V; P=0.002), bi-lobar liver metastases ( P=0.048), and short doubling time (DT) of the liver tumor ( P=0.028) were characteristics assessable before hepatectomy that independently indicated poorer survival.
  • Recurrence was usually extrahepatic in stage IV (patients with Poor/muc) but favored the remnant liver in stage II (patients with bi-lobar metastases or short DT) or III (patients with V; P=0.037).
  • CONCLUSION: Pre-hepatectomy prognostic staging should help to guide treatment of liver metastases.
  • [MeSH-major] Colorectal Neoplasms. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Disease-Free Survival. Female. Follow-Up Studies. Humans. Liver / pathology. Male. Multivariate Analysis. Neoplasm Staging. Prognosis. Risk. Survival Analysis. Time Factors. Tomography, Spiral Computed. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):292-6 [10336810.001]
  • [Cites] Br J Surg. 1992 Oct;79(10):1095-101 [1330197.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):749-54 [7172942.001]
  • [Cites] Eur J Cancer. 1995;31A(1):41-6 [7695977.001]
  • [Cites] Eur J Surg Oncol. 1995 Feb;21(1):33-5 [7851549.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] Ann Surg. 1997 Nov;226(5):582-6 [9389391.001]
  • [Cites] World J Surg. 1987 Aug;11(4):541-7 [3630198.001]
  • [Cites] Surgery. 1994 Oct;116(4):703-10; discussion 710-1 [7940169.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):129-32 [7881931.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):773-81 [7171456.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):163-71 [6722741.001]
  • [Cites] Ann R Coll Surg Engl. 1994 Jan;76(1):59-64 [8117023.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):59-66 [10636103.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):377-81 [7796016.001]
  • [Cites] Am J Surg. 1988 Mar;155(3):378-82 [3344897.001]
  • [Cites] Scand J Gastroenterol Suppl. 1988;149:144-9 [3201153.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S22-31 [14530655.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Surgery. 1998 Jul;124(1):57-64 [9663252.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1956 Nov;76(5):988-1000 [13362715.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1129-33 [11571947.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):887-94 [11521792.001]
  • [Cites] Br J Surg. 1992 Feb;79(2):146-8 [1555063.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] Surgery. 1994 Jun;115(6):674-7 [8197557.001]
  • [Cites] J Am Coll Surg. 1997 Dec;185(6):554-9 [9404879.001]
  • [Cites] Surgery. 1986 Oct;100(4):804-10 [3764701.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):347-53 [11352309.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):797-801 [1873704.001]
  • (PMID = 15605168.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Kitami CE, Kurosaki I, Koyama Y, Makino H, Hatakeyama K: Long-term survival after hepatectomy for hepatic recurrence of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg; 2005;12(4):321-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present herein a rare case of a long-term survivor after major hepatectomy performed for a metastatic liver tumor from carcinoma of the papilla of Vater.
  • Histologically, an exposed mass-forming type of tumor, measuring 40 x 30 mm, was composed of mucinous and papillary adenocarcinoma, invading into the muscularis propria of the duodenum, without lymph node metastases.
  • The patient did not receive any type of chemotherapy.
  • In September 1999, a solitary hepatic tumor, 3.5 cm in diameter, was detected in segment VIII of the liver by computed tomography.
  • After the hepatectomy, the patient was treated with low-dose tegafur/uracil/cisplatin therapy for approximately 2 years.
  • Hepatectomy for hepatic metastases from carcinoma of the papilla of Vater is thought to be a useful surgical treatment in selected patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Humans. Male. Pancreaticoduodenectomy. Tegafur / therapeutic use. Treatment Outcome. Uracil / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133701.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


20. Oneç B, Oksüzoğlu B, Hatipoğlu HG, Oneç K, Azak A, Zengin N: Cavernous sinus syndrome caused by metastatic colon carcinoma. Clin Colorectal Cancer; 2007 Jul;6(8):593-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cranial metastasis has been reported as infrequent during colon cancers and usually occurs in the late stages with liver and/or lung metastasis.
  • A 34-year-old man underwent a right hemicolectomy for a mucinous adenocarcinoma of the right colon 14 months before presentation.
  • Because metastatic implants on the omentum were detected during the operation, combination chemotherapy was begun.
  • After 5 months of the last cycle of the chemotherapy, his left eyelid began to droop, left eye movements became limited, and he began experiencing numbness of his right forehead and cheek.
  • Despite antiedematous treatment and radiation therapy, he did not experience marked improvement of his symptoms.
  • He could not be given chemotherapy and died 2.5 months after the first symptom of cavernous sinus metastasis.
  • Primary colon adenocarcinoma with cavernous sinus metastasis is very rare.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Cavernous Sinus. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681107.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Wang ZH, Guo J, Chen Z, Li CZ, Sheng LJ, Zhou DG, Liu B, Liu J, Wang QC, Zhang EN: [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2008 May;30(5):389-91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The time to progression (TTP) was 9.2 months, and median survival time (MST) was 13.7 months.
  • The RRs of 11 chemotherpy-naïve patients and 26 patients pre-treated with chemotherapy were 81.8% and 61.5%, respectively.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leukopenia / chemically induced. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Remission Induction. Taxoids / administration & dosage. Taxoids / adverse effects. Vomiting / chemically induced. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953843.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Li JQ, Miki H, Ohmori M, Wu F, Funamoto Y: Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol; 2001 Sep;32(9):945-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To examine the roles of their expression in the progression of colorectal carcinoma, 21 normal mucosa, 9 hyperplastic polyps, 58 adenomas, 17 adenocarcinoma in adenomas, 203 primary cancers, 21 lymph node metastases, and 10 hepatic metastases were immunohistochemically stained with anti-cyclin E, anti-CDK2, and anti-Ki67 antibodies.
  • From the primary to the liver-metastatic foci, cyclin E apparently decreased, and CDK2 was reduced almost to zero.
  • In primary carcinomas, the reduction of cyclin E was significantly associated with large tumor size, mucinous type, venous invasion, deep infiltration, lymph nodal metastasis, peritoneal metastasis, advanced stage, and poor prognosis.
  • Anti-cyclin E or anti-CDK2 chemotherapy should be targeted to the cancers with such overexpression.
  • [MeSH-major] Adenocarcinoma / metabolism. CDC2-CDC28 Kinases. Colorectal Neoplasms / metabolism. Cyclin E / metabolism. Cyclin-Dependent Kinases / metabolism. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Colon / metabolism. Colon / pathology. Cyclin-Dependent Kinase 2. Disease-Free Survival. Humans. Hyperplasia. Immunoenzyme Techniques. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Intestinal Polyps / metabolism. Intestinal Polyps / pathology. Ki-67 Antigen / metabolism. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11567224.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cyclin E; 0 / Ki-67 Antigen; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


23. Takano S, Honda I, Watanabe S, Soda H, Nagata M, Hoshino I, Takenouchi T, Miyazaki M: PIVKA-II-producing advanced gastric cancer. Int J Clin Oncol; 2004 Aug;9(4):330-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a 68-year-old man with primary advanced adenocarcinoma of the stomach, who displayed extremely high plasma levels of protein induced by vitamin K antagonist (PIVKA)-II (15 600 mAU/ml) and normal levels of alphafetoprotein (AFP) (4 ng/ml).
  • Ultrasonography and dynamic computed tomography ruled out hepatocellular carcinoma (HCC) or liver metastasis.
  • After preoperative chemotherapy, pancreatico-spleno total gastrectomy with D2 lymphadenectomy was performed.
  • Microscopic examination revealed stomach adenocarcinoma showing various histological types, such as moderately to poorly differentiated mucinous adenocarcinoma, but hepatoid differentiation of gastric adenocarcinoma was not detected.
  • Some cases of PIVKA-II- and AFP-producing advanced gastric cancer with liver metastasis have been reported, but this is the first report of gastric cancer without liver metastasis producing PIVKA-II alone.
  • [MeSH-major] Adenocarcinoma / metabolism. Protein Precursors / biosynthesis. Prothrombin / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Aged. Biomarkers / analysis. Digestive System Surgical Procedures. Humans. Male. Neoplasm Staging. Treatment Outcome. alpha-Fetoproteins / analysis. alpha-Fetoproteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15375711.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  • [Number-of-references] 19
  •  go-up   go-down


24. Fogarasi MC, Zelkowitz RS, Messana SA, Arrighi JA, Seibyl JP, Kummar S: Positron emission tomography for the evaluation of patients with colorectal cancer. Clin Colorectal Cancer; 2001 Aug;1(2):117-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography for the evaluation of patients with colorectal cancer.
  • In a few patients, however, the asymptomatic rise in CEA is not accompanied by diagnostic findings on computed tomography (CT).
  • We report a case herein, of a patient with rising CEA, noted 1 year after completion of adjuvant chemotherapy for node-positive colorectal cancer.
  • In order to further evaluate the rise in CEA, positron emission tomography (PET) was performed.
  • PET revealed an area of increased uptake in the right lobe of the liver.
  • Resection of the metastatic liver lesion resulted in a subsequent drop in the CEA levels.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Cecal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Tomography, Emission-Computed / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoembryonic Antigen / blood. Colectomy. Combined Modality Therapy. Female. Fluorodeoxyglucose F18. Hepatectomy. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Radioimmunodetection / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445370.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


25. Caruba T, Cottu PH, Madelaine-Chambrin I, Espié M, Misset JL, Gross-Goupil M: Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. Breast J; 2007 Mar-Apr;13(2):165-71
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median number of regimen of previous metastatic chemotherapy administered was 3.
  • Grades 3 and 4 peripheral neuropathy were developed by 9% of the patients, but was not limiting.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / therapy
  • [MeSH-minor] Adult. Aged. Anthracyclines / administration & dosage. Anthracyclines / adverse effects. Bridged Compounds / administration & dosage. Bridged Compounds / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Drug-Induced Liver Injury. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Middle Aged. Neoadjuvant Therapy. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Peripheral Nervous System Diseases / chemically induced. Pilot Projects. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319858.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Bridged Compounds; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 1605-68-1 / taxane; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


26. Longo R, Morabito A, Carillio G, Lanzi G, Castellana MA, Amici S, Fanelli M, Gattuso D, Gasparini G: Multiorganic dissemination of a colorectal signet ring cell carcinoma with fulminant clinical course. Int J Gastrointest Cancer; 2006;37(1):49-54
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous colorectal cancer with signet ring cell aspects is a rare form of adenocarcinoma representing about 2-5% of large bowel neoplasms.
  • Local recurrence and distant metastases are common in spite of surgical operation and adjuvant treatment, conditioning a poor prognosis.
  • At the present, early diagnosis and complete resection are the most important approaches to improve the outcome.
  • The fulminant tumor progression was really unexpected and misled every possible medical interpretation, leading to rapid worsening of the patient's clinical conditions and no chance for chemotherapy treatment.
  • The tumor mimicked the picture observed in the acute leukemia, developing diffuse infiltration in all serosal membranes, liver, lung, kidneys, multiple lymph nodes, and meninges, as revealed by the post-mortem medical report.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology. Neoplasm Metastasis / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1991 Sep-Oct;76(5):368-74 [1806439.001]
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10):2195-9 [8855747.001]
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):344-8 [8790846.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):244-9 [15492759.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Arch Pathol Lab Med. 1991 Oct;115(10):1022-5 [1654871.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Tumori. 1996 Jul-Aug;82(4):408-12 [8890982.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):183-8 [10981869.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1453-7 [6311394.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1189-92 [7587762.001]
  • [Cites] Am J Med. 1976 Feb;60(2):273-8 [1062163.001]
  • (PMID = 17290081.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Hu YJ, Ip PP, Chan KK, Tam KF, Ngan HY: Ovarian clear cell carcinoma with choriocarcinomatous differentiation: report of a rare and aggressive tumor. Int J Gynecol Pathol; 2010 Nov;29(6):539-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation.
  • A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases.
  • She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response.
  • Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively.
  • Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Choriocarcinoma, Non-gestational / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Fatal Outcome. Female. Gynecologic Surgical Procedures. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881859.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2008 Jan 1;26(1):83-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate regression analysis revealed that histology, malignant pleural effusion, intraparenchymal liver metastasis, and residual tumor size were significant prognostic variables.
  • Patients with less than 5.0 cm of disease initially and significant disease and/or comorbidities precluding microscopic cytoreduction may be considered for alternative therapeutic options other than primary cytoreduction.
  • [MeSH-major] Neoplasm, Residual / etiology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Follow-Up Studies. Humans. Medical Records. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pleural Effusion, Malignant / etiology. Postoperative Complications / etiology. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 1;26(10):1771-2; author reply 1772 [18375912.001]
  • (PMID = 18025437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, Numa F, Okada M, Aotani E: Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. Int J Gynecol Cancer; 2009 Jul;19(5):834-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the antitumor efficacy and safety of 2 treatment modalities: intraperitoneal carboplatin combined with intravenous (IV) paclitaxel.
  • Nonhematological toxicities included G2 liver function, 4%; G3 sensory neuropathy, 8%; and G3 myalgia and arthralgia, 4%.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Endometrial Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Maximum Tolerated Dose. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574769.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. Dodiuk-Gad R, Ziv M, Loven D, Schafer J, Shani-Adir A, Dyachenko P, Rozenman D: Sister Mary Joseph's nodule as a presenting sign of internal malignancy. Skinmed; 2006 Sep-Oct;5(5):256-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A skin biopsy from the nodule showed mucinous adenocarcinoma.
  • These results were consistent with a Sister Mary Joseph's nodule and led to the diagnosis of an occult colon carcinoma.
  • The patient underwent surgery in another hospital, and died 3 months after the initial diagnosis of Sister Mary Joseph's nodule.
  • An abdominopelvic CT scan demonstrated a 3.5-cm space-occupying lesion in the liver.
  • She died 4 months after the initial diagnosis of umbilical metastasis.
  • The mass was removed and diagnosed as a poorly differentiated adenocarcinoma, staining positively for carcinoembryonic antigen, and negatively for CK20, CK7, prostate-specific antigen, and prostatic acid phosphatase.
  • On bronchoscopy, it was found to be an invasive adenocarcinoma, consistent with a primary tumor of the lung.
  • The patient received 4 cycles of combined chemotherapy with carboplatine and gemcitabine, with no improvement.
  • Following demonstration of intra-abdominal spread of disease by CT scan, a second line chemotherapy was instituted with paclitaxel.
  • The patient died 3 weeks later, 9 months after the diagnosis of adenocarcinoma of the lung.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957443.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Malani AK, Olofsson B, Debono D: Remission of hepatic metastasis from colon cancer after methotrexate withdrawal. Am J Med; 2006 Apr;119(4):366-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Antirheumatic Agents / administration & dosage. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Methotrexate / administration & dosage. T-Lymphocytes, Cytotoxic / drug effects
  • [MeSH-minor] Aged. Arthritis, Rheumatoid / drug therapy. Colectomy. Humans. Lymphocyte Activation. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564789.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement